Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Down 13.6% in February

Adlai Nortye Ltd. (NASDAQ:ANL) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 3,800 shares, a decrease of 13.6% from the January 31st total of 4,400 shares. Based on an average daily trading volume, of 9,100 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a report on Monday, November 11th.

Adlai Nortye Stock Performance

Shares of ANL opened at $2.22 on Friday. Adlai Nortye has a 12 month low of $1.85 and a 12 month high of $17.48. The firm has a fifty day simple moving average of $2.17 and a 200 day simple moving average of $2.28.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.